platinum has been researched along with Local Neoplasm Recurrence in 239 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (1.67) | 18.7374 |
1990's | 5 (2.09) | 18.2507 |
2000's | 14 (5.86) | 29.6817 |
2010's | 105 (43.93) | 24.3611 |
2020's | 111 (46.44) | 2.80 |
Authors | Studies |
---|---|
Cai, J; Cai, Q; Fang, Y; Huang, H; Li, Z; Liu, P; Ma, S; Su, N; Tian, X; Wang, J; Xia, Y; Zhang, Y | 1 |
Demachi, K; Fujita, T; Fujiwara, H; Kojima, T; Kotani, D; Okunaka, M; Sakashita, S; Yoshino, T | 1 |
Abdeddaim, C; Anota, A; Brocard, F; Cancel, M; Floquet, A; Frenel, JS; Hardy-Bessard, AC; Houlier, A; Kalbacher, E; Lardy-Cleaud, A; Largillier, R; Levaché, CB; Lortholary, A; Louvet, C; Meunier, J; Mouret-Reynier, MA; Pissaloux, D; Pop, O; Provansal, M; Ray-Coquard, I; Savoye, AM; Trédan, O; Treilleux, I; Venat-Bouvet, L; You, B; Zannetti, A | 1 |
Coleman, RL; Lainé, A; Le Saux, O; Ray-Coquard, I; Sims, TT | 1 |
Choi, MC; Jeong, DH; Kim, BG; Kim, SI; Lee, JK; Lee, JY; Lim, MC; Park, J | 1 |
Barnicle, A; Bennett, J; Bjurberg, M; Blakeley, C; Cibula, D; Colombo, N; Davidson, R; González-Martín, A; Ledermann, J; Lheureux, S; Lindemann, K; Madry, R; Oaknin, A; Pérez, MJR; Poveda, A; Sikorska, M; Škof, E; Weberpals, J | 1 |
Kang, YK; Koo, DH; Lee, MY; Moon, MS; Ryu, MH | 1 |
Abadie-Lacourtoisie, S; Blanc-Fournier, C; Brachet, PE; Briand, M; Clarisse, B; Fabbro, M; Floquet, A; Follana, P; Frenel, JS; Gavoille, C; Giffard, F; Gladieff, L; Joly, F; Just, PA; Kalbacher, E; Leary, A; Leconte, A; Lequesne, J; Lesoin, A; Medioni, J; Poulain, L; Weiswald, LB; You, B | 1 |
Jimi, T; Kitai, M; Nagao, S; Nakazawa, H; Narita, M; Shibutani, T; Shiozaki, T; Yamaguchi, S; Yano, H | 1 |
Akilli, H; Aliyeva, K; Altundag, O; Ayhan, A; Kuscu, UE; Rahatli, S | 1 |
Cai, J; Chen, B; Hu, Y; Jiang, W; Luo, X; Wei, L; Xu, P | 1 |
Ikeda, Y; Iyoshi, S; Kajiyama, H; Kato, M; Kikkawa, F; Kitami, K; Koya, Y; Mogi, K; Ohnuma, S; Sugiyama, M; Tamauchi, S; Tazaki, A; Uno, K; Yokoi, A; Yoshihara, M; Yoshikawa, N | 1 |
Endoh, H; Fujita, A; Imai, H; Kaburagi, T; Kaira, K; Kanazawa, K; Kasai, T; Kiyoshima, M; Kotake, M; Matsuguma, H; Minato, K; Minemura, H; Nakamura, Y; Sugiyama, T; Suzuki, H; Yamada, Y | 1 |
Arenare, L; Baldassarre, G; Bartoletti, M; Califano, D; Capoluongo, E; Chiodini, P; Costi, MP; D'Incalci, M; Greggi, S; Marchini, S; Mezzanzanica, D; Musacchio, L; Normanno, N; Perrone, F; Pignata, S; Scala, S; Schettino, C | 1 |
Date, H; Inoue, A; Kawaguchi, T; Kenmotsu, H; Kiura, K; Miyaoka, E; Miyawaki, E; Okamoto, I; Sekine, I; Shintani, Y; Shukuya, T; Takahashi, K; Takayama, K; Yamamoto, N; Yoshino, I | 1 |
Chi, J; Gao, QL; Huo, Y; Jiang, J; Jiao, X; Li, G; Li, M; Li, R; Liu, J; Liu, X; Ma, G; Peng, Z; Song, C; Yu, Y; Zeng, S; Zhang, W; Zhao, Y | 1 |
Blumenschein, G; Colevas, AD; Even, C; Fayette, J; Ferris, RL; Gillison, ML; Guigay, J; Haddad, R; Harrington, KJ; Iglesias Docampo, LC; Jayaprakash, V; Kasper, S; Kiyota, N; Licitra, L; Rordorf, T; Saba, NF; Tahara, M; Vokes, EE; Wei, L; Worden, F | 1 |
Ghobashi, AH; Huntington, TD; Metcalfe, TX; Nephew, KP; O'Hagan, HM; Sood, R; Sriramkumar, S; Vuong, TT; Wang, W | 1 |
Kang, M; Li, C; Li, Z; Liu, T; Song, J; Yang, D; Zhou, L; Zhou, Z | 1 |
Ali, WA; Fang, WF; Gan, JD; Huang, YH; Liao, J; Lv, Y; Pang, LL; Zhang, L | 1 |
Li, Y; Liu, C; Sun, L | 1 |
Hirota, M; Kawada, J; Kawakami, H; Kii, T; Kurokawa, Y; Matsuyama, J; Nomura, M; Ohta, T; Sakai, D; Satoh, T; Shimokawa, T; Tsujinaka, T | 1 |
Aoki, D; Chiyoda, T; Kobayashi, Y; Kuroda, Y; Nanki, Y; Sakai, K; Saotome, K; Takahashi, M; Yamagami, W; Yoshihama, T; Yoshimura, T | 1 |
Karl, F; Krenzer, S; Link, T; Maywald, U; Mevius, A; Wacker, M; Welte, R; Wilke, T | 1 |
Chen, Q; Huang, J; Lin, L; Lv, D; Pan, W; Wu, G; Wu, X; Yan, S | 1 |
Cao, Y; Chen, J; Hou, H; Li, C; Wang, J; You, J; Yuan, Z; Zhang, B; Zhu, L | 1 |
Carlisle, J; Chen, Z; Dhodapkar, M; Leal, T; Liu, Y; Osta, BE; Owonikoko, T; Pakkala, S; Ramalingam, S; Steuer, C | 1 |
Pasquini, L; Petrucci, E; Riccioni, R | 1 |
Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T | 1 |
Guo, Y; Liu, Y; Xia, Z; Xue, L; Zhang, Q | 1 |
Baudin, E; Beaulaton, C; Blanchet, O; Chatelain, D; Do Cao, C; Ducreux, M; Faron, M; Hadoux, J; Hautefeuille, V; Hervieu, V; Hescot, S; Joubert Zakeyh, J; Kanaan, C; Laboureau, S; Leteurtre, E; Lombard-Bohas, C; Marchal, A; Perrier, M; Petorin, C; Rousselet, MC; Scoazec, JY; Tauveron, I; Walter, T | 1 |
Fang, F; Lai, T; Metcalfe, TX; Nephew, KP; O'Hagan, HM; Sriramkumar, S; Zong, X | 1 |
Agami, R; Amant, F; Annibali, D; Baiden-Amissah, REM; Berardi, E; Berkers, CR; Carmeliet, P; Davidson, B; De Wispelaere, W; Duarte, JAG; Eelen, G; Fendt, SM; Horlings, HM; Körner, PR; Lambrechts, D; Moens, S; Planque, M; Rizzotto, L; Rossi, M; Sonke, GS; Swinnen, JV; Talebi, A; Van Nyen, T; van Wagensveld, L; Zaal, EA | 1 |
Chen, X; Cheng, X; Dong, J; Guo, W; Ni, J; Xiao, L; Xu, X; Xue, Q; Zhao, Q | 1 |
Berger, J; Boisen, M; Buckanovich, R; Coffman, LG; Courtney-Brooks, M; Edwards, RP; Frisbie, LG; Griffith, K; Lesnock, J; Liu, T; Mahdi, H; McLean, K; Normolle, D; Olawaiye, A; Orellana, TJ; Sukumvanich, P; Taylor, SE; Uppal, S | 1 |
Bessho, A; Furuya, N; Goto, Y; Harada, T; Kawashima, Y; Misumi, T; Miura, S; Nakahara, Y; Nakamura, Y; Naoki, K; Okamoto, H; Seike, M; Shimokawa, T; Shiraishi, Y; Takiguchi, Y; Tanaka, H; Taniguchi, Y; Tokito, T; Uchiyama, A | 1 |
Abe, M; Aida, T; Baba, T; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takatori, E; Tatsuki, S; Tomabechi, H | 1 |
Chen, LH; Du, Y; Ouyang, HF; Ti, XY; Wu, S; Xu, X; Zhang, Y | 1 |
Imai, H; Kaburagi, T; Kagamu, H; Kaira, K; Kanazawa, K; Kishikawa, T; Masubuchi, K; Minato, K; Minemura, H; Nagai, Y; Shiihara, J; Shiono, A; Takechi, H; Taniguchi, H; Tsuda, T; Umeda, Y; Wasamoto, S; Yamada, Y | 1 |
Bae, BK; Cho, WK; Choi, CH; Kim, TJ; Lee, JW; Lee, YY; Park, W | 1 |
Fushimi, C; Hanyu, K; Ito, T; Kondo, T; Masubuchi, T; Matsuki, T; Miura, K; Okada, T; Okamoto, I; Omura, GO; Oridate, N; Sato, H; Tada, Y; Takahashi, H; Tokashiki, K; Tsukahara, K; Yamashita, T | 1 |
Colombo, N; Credille, KM; Gao, B; Konstantinopoulos, PA; Lee, JM; Lee, JY; Lin, AB; McNeely, S; Miller, R; Shapira-Frommer, R; Vergote, I; Wang, XA; Young, SR | 1 |
Baba, T; Furukawa, S; Kagabu, M; Kaiho-Sakuma, M; Matsumura, Y; Nagasawa, T; Nagase, S; Ohta, T; Seino, M; Shigeta, S; Shigeto, T; Shimada, M; Shimizu, D; Shoji, T; Soeda, S; Takahashi, F; Takatori, E; Terada, Y; Tokunaga, H; Watanabe, T; Yokoyama, Y | 1 |
Ho, AL | 1 |
Bossi, P; Caldara, A; Canevari, S; Caponigro, F; Carenzo, A; Cavalieri, S; De Cecco, L; Denaro, N; Ferrari, D; Ferraù, F; Lenoci, D; Licitra, L; Miceli, R; Moretti, G; Moro, C; Pistore, F; Rinaldi, G; Rocca, MC; Secondino, S; Serafini, MS; Sponghini, A; Vaccher, E; Vecchio, S | 1 |
Fujii, T; Fujimoto, Y; Gumuscu, B; Hanai, N; Hara, H; Matsumoto, K; Mitsugi, K; Nakayama, M; Nohata, N; Oridate, N; Shiga, K; Shimizu, Y; Swaby, RF; Tahara, M; Takahashi, K; Takahashi, M; Takahashi, S; Tanaka, K; Ueda, T; Yamaguchi, H; Yamazaki, T; Yasumatsu, R; Yokota, T; Yoshizaki, T | 1 |
Aghajanian, C; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; Gancedo, MA; Goble, S; Goh, JC; Holloway, RW; Kwan, T; Leary, A; Ledermann, JA; Lin, KK; Lorusso, D; Maloney, L; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI | 1 |
Chen, M; Jiang, Q; Li, J; Li, T; Luo, X; Sun, Y; Yao, L; Yuan, L | 1 |
Balmaña, J; Banerjee, S; Borrow, J; Burris, HA; Chen, LM; Domchek, SM; Drew, Y; Glasspool, RM; Goble, S; Kristeleit, RS; Lin, KK; Maloney, L; Oza, AM; Patel, MR; Safra, T; Shapira-Frommer, R | 1 |
Arunachalam, A; Catherine Pietanza, M; Frederickson, AM; Zhang, I; Zhao, B | 1 |
Cabezas-Camarero, S; Cabrera-Martín, MN; Cerezo Druet, E; Iglesias-Moreno, MC; Merino-Menéndez, S; Pérez-Segura, P; Plaza-Hernández, JC; Sotelo, MJ | 1 |
Aglietta, M; Arcangeli, V; Barretina-Ginesta, MP; Benedetti Panici, P; Berger, R; Biagioli, E; Bologna, A; Chekerov, R; Churruca Galaz, C; Colombo, N; D'Incalci, M; De Giorgi, U; DeCensi, A; Deryal, M; Fossati, R; Funari, G; Gadducci, A; Heinzelmann-Schwarz, V; Herbertson, R; Iglesias, M; Mäenpää, J; Mirza, MR; Montes, A; Nyvang, GB; Ottevanger, NB; Pardo, B; Poveda, A; Riniker, S; Romeo, M; Rubio-Pérez, MJ; Rulli, E; Sehouli, J; Sessa, C; Tasca, G; Tognon, G; Tsibulak, I; Vergote, I; Westermann, A; Wimberger, P; Zamagni, C; Zola, P | 1 |
Abd Aziz, NHB; Atallah, GA; Chew, KT; Kampan, NC; Md Zin, RR; Mohd Mokhtar, N; Shafiee, MNB | 1 |
Campbell, SR; Geiger, JL; Koyfman, S; Lopetegui-Lia, N; Roof, L; Schwartzman, LM; Silver, N; Woody, NM; Yalamanchali, A; Yang, K; Yilmaz, E | 1 |
Crosbie, EJ; Edmondson, RJ; Faraahi, ZF; Gavrielides, N; Hawarden, A; Jones, DM; McCormick, A; Price, MJ; Roberts, C; Russell, B; Tyagi, S; Waddell, CA; Walker, TDJ; Whalley, B; Woodhouse, LC | 1 |
Allonby, O; Boyne, DJ; Brenner, DR; Cheung, WY; Habash, M; Martins, D; McGee, J; O'Sullivan, DE; Riemer, J | 1 |
Balbach, ML; Bestvina, C; Camidge, DR; Hsu, R; Iams, WT; Kim, C; Leal, T; Marmarelis, ME; Mehta, K; Nieva, J; Patil, T; Phillips, S; Robinson, MA; Sacher, A; Sackstein, PE; Sethakorn, N; Velcheti, V; Wang, X | 1 |
Gou, S; Wang, X; Wang, Y | 1 |
Brennan, DJ; Doran, P; Glennon, K; Jeronimo, C; Lynch, L; Martin, T; Metoudi, M; Moran, B; Perry, AS; Salta, S; Shaw, J; Silva, R; Slattery, K; Treacy, A | 1 |
Aghajanian, C; Chi, DS; Chui, MH; Girshman, J; Gordhandas, S; Grisham, RN; Iasonos, A; Kahn, RM; Laibangyang, A; Long Roche, K; Manning-Geist, BL; Nemirovsky, D; Zivanovic, O | 1 |
Acharya, R; Anderson, JL; Delgoffe, GM; Ferris, RL; Harris, AL; Hsieh, RW; Li, J; Menk, AV; Nilsen, ML; Scheff, NN; Swartz, A; Zandberg, DP | 1 |
Arndt, T; Belau, AK; Braicu, EI; Canzler, U; Chekerov, R; de Gregorio, N; Mahner, S; Mustea, A; Neunhoeffer, T; Pietzner, K; Richter, R; Sehouli, J; Stocker, G; Strauß, HG; von Abel, E; Wimberger, P; Woelber, L; Yalinkaya, I | 1 |
Gao, Q; Huang, S; Jiang, Y; Jin, L; Li, B; Li, T; Lin, Y; Mao, X; Nowialis, P; Song, L; Song, Q; Xing, C; Zheng, G | 1 |
Argiris, A; Bratland, Å; Chung, CH; Coutte, A; de Azevedo, S; Even, C; Fayette, J; Ferris, RL; Gillison, M; Grant, C; Grell, P; Haddad, R; Hansen, AR; Harrington, KJ; Khan, TA; Miller-Moslin, K; Redman, R; Roberts, M; Salas, S; Schenker, M; Soulières, D; Tahara, M; Walker, JWT; Wei, L | 1 |
Bonomo, P; Borcoman, E; Cau, MC; Depenni, R; Ghi, MG; Ghiani, M; Le Tourneau, C; Leo, L; Messinger, D; Montesarchio, V; Ronzino, G; Salmio, S; Sbrana, A; Schulten, J | 1 |
Kanai, M; Kondo, T; Matsumori, T; Murakami, H; Muto, M; Nagai, K; Sunami, T; Uchida, Y; Uza, N; Yamada, A; Yamada, T; Yokode, M | 1 |
Eskander, RN; O'Malley, DM; Richardson, DL | 1 |
Alamgeer, M; Cain, JE; Chen, J; DeVeer, M; Ganju, V; Garama, DJ; Gough, DJ; Guanizo, AC; Inampudi, C; Jakasekara, WSN; Luong, Q; Thakur, N; Watkins, DN | 1 |
Hamontri, S; Tantitamit, T | 1 |
Bramhecha, Y; Dorigo, O; Ebrahimizadeh, W; Fiset, S; Ghamande, S; Ghatage, P; Hirsch, HA; Kaliaperumal, V; MacDonald, LD; Oza, AM; Pejovic, T; Provencher, D; Torrey, H; Villella, J | 1 |
Borgonovo, K; Celotti, A; Ghidini, A; Lorusso, D; Luciani, A; Petrelli, F; Rea, CG; Solinas, C; Villa, A | 1 |
Asanoma, K; Hachisuga, K; Hori, E; Kato, K; Kodama, K; Maenohara, S; Ohgami, T; Okugawa, K; Onoyama, I; Yagi, H; Yahata, H; Yasunaga, M | 1 |
Chao, HS; Chen, YM; Chiang, CL; Hsiao, TH; Huang, HC; Liao, YT; Luo, YH; Shen, CI; Sun, RL; Tseng, YH; Wang, LC; Yeh, YC | 1 |
Atsumi, K; Hirose, T; Hisakane, K; Nishijima, N; Okano, T; Seike, M; Takahashi, S; Taniuchi, N; Tozuka, T | 1 |
Awazu, Y; Fukuda, T; Ichimura, T; Imai, K; Noda, T; Sumi, T; Tasaka, R; Uchikura, E; Yamauchi, M; Yasui, T | 1 |
Borel, C; Chevalier, T; Collet, L; Daste, A; Fayette, J; Huguet, F; Richard, S; Saada-Bouzid, E; Salas, S; Tardy, M; Vienne, A | 1 |
Ito, T; Okada, T; Okamoto, I; Tokashiki, K; Tsukahara, K; Yamashita, G | 1 |
Huang, Z; Li, D; Lin, L; Liu, Z; Zhang, G; Zhong, J; Zhuang, W | 1 |
Augusto, I; Cruz, A; Mansinho, A; Marconi, L; Pinto, C | 1 |
Akamatsu, H; Hida, T; Inui, N; Kang, JH; Kim, HR; Lee, JS; Lee, KH; Nakagawa, K; Nishio, M; Ohe, Y; Sugawara, S; Takahashi, S; Tamura, T; Tanaka, H; Yamamoto, N; Yang, CT; Yoshida, T; Yu, CJ | 1 |
Belin, L; Bultot-Boissier, É; Churruca, C; Cibula, D; D'Hondt, V; de Gregorio, N; Denys, H; Gaba, L; Heitz, F; Heudel, PE; Joly, F; Kocián, R; Kurtz, JE; Largillier, R; Lebreton, C; Leitner, K; Lotz, JP; Martinez García, J; Mouret Reynier, MA; Oaknin, A; Pautier, P; Petru, E; Polterauer, S; Pujade-Lauraine, E; Rodrigues, M; Rosengarten, O; Schmalfeldt, B; Sehouli, J; Selle, F; Vergote, I | 1 |
Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
Bu, H; Feng, S; Huang, Y; Jin, C; Kong, B; Li, N; Liu, J; Ma, Y; Song, K; Wen, H; Wu, L; Yang, X; Zhang, H | 1 |
Ahn, MJ; Burtness, B; Cohen, EEW; Dinis, J; Ge, J; Harrington, KJ; Lerman, N; Licitra, L; Lin, J; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Tourneau, CL | 1 |
Cao, Y; Hua, F; Luo, J; Wang, D; Wang, X; Xiao, W | 1 |
Bouberhan, S; Cannistra, SA; Pujade-Lauraine, E | 1 |
Banerjee, S; Pignata, S; Pujade-Lauraine, E | 1 |
Schorge, JO | 1 |
Frank, K; Kramer, M; Kuhlmann, JD; Link, T; Passek, S; Vassileva, YD; Wimberger, P | 1 |
Blakeley, C; Davidson, R; Milner, A; Poveda, AM | 1 |
Batista, TP; Kusamura, S | 1 |
Choi, CH; Kim, BG; Kim, HS; Kim, JW; Kim, S; Lee, JY; Lim, J; Nam, BH; Yi, JY | 1 |
Long, X; Zhou, Q; Zou, D | 1 |
Chang, GC; Chen, YM; Chih-Hsin Yang, J; Chiu, CH; Chong, IW; Ho, CC; Hsia, TC; Hung, JY; Lin, MC; Su, WC; Wang, CC; Wu, SY; Yang, TY; Yu, CJ | 1 |
Bajpai, J; Deodhar, K; Ghosh, J; Gulia, S; Gupta, S; Maheshwari, A; Rath, S; Shylasree, TS; Thakur, M | 1 |
Penson, RT | 1 |
Tomao, F; Tomao, S; Vici, P | 1 |
Aghajanian, C; Armstrong, DK; Banerjee, S; Cameron, T; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; Gancedo, MA; García-Donas, J; Goble, S; Goh, JC; Holloway, RW; Leary, A; Ledermann, JA; Lorusso, D; Maloney, L; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI | 1 |
Ahn, JS; Ahn, MJ; Godin, RE; Hollingsworth, SJ; Jung, HA; Kim, HJ; Lee, SH; Mortimer, PGS; Park, K; Park, S; Park, WY; Shim, J; Smith, SA; Sun, JM | 1 |
Balermpas, P; Belka, C; Bergmann, T; Fietkau, R; Göhler, T; Große-Thie, C; Guntinas-Lichius, O; Hahn, D; Hautmann, MG; Hecht, M; Messinger, D; Orlowski, K; Reichert, D; Stenzel, KG; von der Grün, J; Welslau, M; Weniger, S; Wolber, P | 1 |
Goto, M; Hori, K; Ito, K; Onoue, M; Takaki, E; Takei, T; Tashima, L; Tsuji, S; Yamashita, M; Yoshioka, E | 1 |
Chung, HH; Hwang, WY; Kim, HS; Kim, JW; Kim, K; Kim, SI; Kim, YB; Lee, M; No, JH; Park, NH; Song, YS; Suh, DH | 1 |
Ding, H; Fang, Q; Tong, Y; Xin, W; Xu, G; Yang, G; Zheng, X | 1 |
Brown, R; Chiu, DS; Choi, H; Hoppe, MM; Huntsman, DG; Jaynes, P; Jeyasekharan, AD; Karnezis, A; Kaye, SB; Leung, S; Lie, S; Lim, DGZ; Lim, S; P S Yeong, J; Pang, BNK; Patel, NR; Pitt, JJ; Sato, K; Scott, CL; Sedukhina, AS; Tan, DSP; Tan, TZ; Topp, MD; Upadhyayula, SS; Wardyn, JD | 1 |
Aghajanian, C; Beltman, J; Brenton, JD; Castro, C; Chen, LM; Coleman, RL; Goble, S; Green, M; Harding, T; Konecny, GE; Kristeleit, RS; Leary, A; Lin, KK; Ma, L; Maloney, L; McNeish, IA; O'Malley, DM; Oaknin, A; Oza, AM; Provencher, D; Ray-Coquard, I; Shapira-Frommer, R; Simmons, AD; Swisher, EM; Tinker, AV; Xiao, JJ | 1 |
Arén Frontera, O; Bajars, M; Barlesi, F; Calabrò, L; de Marinis, F; Garassino, M; Ishii, H; Krzakowski, M; Lee, JS; Özgüroğlu, M; Park, K; Polychronis, A; Ruisi, M; Spigel, D; Szczesna, A; Uslu, R; Vansteenkiste, J; Xiong, H; Yang, JCH | 1 |
Aghajanian, C; Chambers, SK; Chen, LM; Coleman, RL; Dobrovic, A; Dominy, E; Dorigo, O; Elvin, JA; Ghatage, P; Giordano, H; Goble, S; Harding, T; Kaufmann, SH; Konecny, GE; Kristeleit, RS; Kwan, TT; Leary, A; Lin, DI; Lin, KK; Ma, L; Maloney, L; McNeish, IA; Musafer, A; O'Malley, DM; Oaknin, A; Oza, AM; Provencher, D; Ray-Coquard, I; Scott, CL; Swisher, EM; Tinker, AV; Vo, LT; Wahner Hendrickson, AE; Welch, S | 1 |
Dai, T; Liu, S; Lv, S; Pei, R; Shi, Y; Wu, B; Zhang, F | 1 |
Cass, I; Kamrava, M; Karlan, B; Kim, S; Li, A; Rimel, BJ; Rogatko, A; Walsh, CS | 1 |
Kim, HS; Lee, M; Lee, N; Lee, S; Paik, H; Park, SJ; Yim, GW | 1 |
Ishibashi, M; Nagai, T; Niikura, H; Sasaki, S; Shigeta, S; Shimada, M; Tokunaga, H; Toyoshima, M; Tsuji, K; Yaegashi, N | 1 |
Fujisaki, M; Fujita, S; Futawatari, N; Kikuchi, Y; Mitsumori, N; Murakami, M; Nagaoka, S; Oshima, Y; Otsuka, K; Seto, Y; Shimada, H; Yajima, S; Yamashita, H | 1 |
Abakumova, TV; Antoneeva, II; Dolgova, DR; Gening, SO; Gening, TP | 1 |
Havrilesky, LJ; Moss, HA; Perhanidis, JA; Secord, AA | 1 |
Elzarkaa, AA; Malik, E; Soliman, AA | 1 |
Adorno-Cruz, V; Berry, E; Cowan, M; Kocherginsky, M; Lurain, JR; Matei, D; Nelson, V; Neubauer, NL; O'Shea, KL; Pineda, MJ; Shahabi, S; Swetzig, WM; Taiym, D | 1 |
Choi, MC; Hwangbo, S; Kim, K; Kim, MK; Kim, SI; Kwak, YH; Lee, JM; Lee, JW; Lee, M; Shim, SH; Shin, SJ; Yoo, J | 1 |
Babu, S; Govind Babu, K; Jacob, L; Lakshmaiah, KC; Lokanatha, D; Lokesh, KN; Rajeev, LK; Rudresha, AH; Sridharmurthy, A; Thanky, AH | 1 |
Li, J; Lin, G; Liu, B; Liu, H; Liu, J; Shang, X | 1 |
Ahuja, A; Aksoy, BA; Bowtell, DDL; Buros, J; Christie, EL; Hammerbacher, J; O'Donnell, T; Snyder, A | 1 |
Fujimoto, E; Okame, S; Okazawa-Sakai, M; Shiroyama, Y; Takehara, K; Yokoyama, T | 1 |
Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Blumenthal, GM; Charlab, R; Chen, XH; Dave, K; Dinin, J; Eradiri, O; Ghosh, S; Goldberg, KB; Horne, HN; Howie, LJ; Ibrahim, A; Ison, G; Janoria, KG; Kelly, SL; Kluetz, PG; Lee, EY; Li, F; Manheng, W; Palmby, TR; Pazdur, R; Philip, R; Pierce, WF; Pierre, V; Ramamoorthy, A; Song, P; Sridhara, R; Tang, S; Yu, J; Zhang, L | 1 |
Komiyama, S; Kubushiro, K; Kugimiya, T; Takahashi, R; Takeya, C | 1 |
Konstantinopoulos, PA; Matulonis, UA | 1 |
Li, X; Ma, X | 1 |
Corrado, G; Ferrandina, G | 1 |
Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD | 1 |
Abuodeh, YA; Dilling, TJ; Grass, GD; Naghavi, AO; Perez, BA | 1 |
Braicu, I; Darb-Esfahani, S; Ganapathi, MK; Ganapathi, RN; Lanchbury, JS; Patel, JN; Reid, J; Sehouli, J; Solimeno, C; Timms, KM; Tshiaba, P | 1 |
du Bois, A; Fielding, A; Friedlander, M; Gourley, C; Ledermann, J; Lowe, ES; Mann, H; Matei, D; Matulonis, U; McMurtry, EL; Meier, W; Parry, D; Rowe, P; Rustin, G; Safra, T; Scott, C; Selle, F; Shapira-Frommer, R; Shirinkin, V; Spencer, S; Vergote, I | 1 |
Beach, JA; Bowtell, DDL; Christie, EL; Freimund, AE | 1 |
Choi, MC; Jeong, DH; Kang, S; Kim, JW; Kim, KH; Kim, TH; Kim, YB; Kim, YM; Lee, IH; Lee, JW; Lee, JY; Lee, KB; Lee, YJ; Park, JY; Park, SY; Pujade-Lauraine, E | 1 |
Alonso, T; Cabezas, S; Callata, HR; Casado, A; Díaz-Rubio, E; Fernández, C; Gajate, P; Manzano, A; Marquina, G; Sotelo, M | 1 |
Black-Shinn, J; Boyd, M; Chirovsky, D; Joo, S; Nadler, E | 1 |
Wu, L; Zhong, L | 1 |
Arakawa, A; Chan, MWY; Katsushima, K; Kondo, Y; Lai, HC; Lin, RI; Mase, S; Shinjo, K; Sugiura-Ogasawara, M; Takahashi, S; Totani, H | 1 |
Aglietta, M; Borella, F; Di Renzo, MF; Erriquez, J; Ferrero, A; Genta, S; Ghisoni, E; Giannone, G; Katsaros, D; Maggiorotto, F; Mittica, G; Sarotto, I; Sciarrillo, A; Valabrega, G | 1 |
Heindl, A; Huang, X; Lan, C; Li, J; Wang, Y; Yan, S; Yuan, Y | 1 |
Amira, G; Fayek, IS; Mansour, O; Morsi, A; Nader, H | 1 |
Gonzalez-Martin, A; Lorusso, D; Pignata, S | 1 |
Isohashi, F; Kimura, T; Kodama, M; Komura, N; Mabuchi, S; Matsumoto, Y; Ogawa, K; Shimura, K; Tomimatsu, T; Yokoi, E | 1 |
Nagao, S | 1 |
Arcusa, Á; Barretina-Ginesta, P; Bover, I; Casado, A; Del Campo, JM; García, Y; González-Martín, A; González-Santiago, S; Guerra, E; Herrero, A; Mallol, P; Martín, L; Martínez, A; Mori, M; Ortega, E; Romero, I; Rubio, MJ; Santaballa, A; Vicente, D; Vidal, L | 1 |
Daignault-Newton, S; Hough, S; Kalemkerian, GP; Reddy, HG; Weis, TM | 1 |
Alconchel, F; Barceló, F; Cascales-Campos, PA; Gil, E; Gil, J; Gómez-Ruiz, ÁJ; González-Gil, A; Martínez, J; Navarro-Barrios, Á; Nieto, A | 1 |
Deshpande, J; Dickson, EL; Geller, MA; Grad, A; Hoostal, S; Klein, M; Linden, MA; Lou, E; Monu, M; Subramanian, S; Teoh, D; Vogel, RI; Wong, P; Łukaszewski, T | 1 |
Al-Ali, H; Azzam, DJ; Brothers, SP; Ince, TA; Lohse, I; Volmar, CH; Wahlestedt, C | 1 |
Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
Barnett, JC; Havrilesky, LJ; Ledermann, JA; Myers, ER; Peterson, BL; Secord, AA | 1 |
Lv, X; Pan, ZH; Su, A; Zhang, J; Zhou, QM | 1 |
Chan, C; Colevas, AD; Jiang, W; Kong, C; Le, QT; Lee-Enriquez, N; Murphy, JD; Pinto, H; Tang, C; von Eyben, R | 1 |
Hu, P; Kang, S; Li, Y; Qi, BL; Wang, N; Zhou, RM | 1 |
Boikos, SA; Brahmer, JR; Ettinger, DS; Forde, PM; Giaccone, G; Hann, CL; Hooker, CM; Illei, PB; Kelly, RJ; Petrini, I; Rudin, CM; Yang, SC | 1 |
Appleton, K; Brown, R; Gabra, H; Glasspool, RM; Gore, ME; Halford, SE; Hall, GD; Kaye, S; Mackean, M; McNeish, IA; Paul, J; Pledge, S; Rustin, GJ; Ullah, R; Walker, J; Wilson, RH | 1 |
Butow, P; Donovan, H; Friedlander, ML; Gillies, K; King, MT; Martyn, J; O'Connell, R; Oza, A; Sjoquist, K; Stockler, M; Voysey, M | 1 |
Allard, A; Bennouna, J; Chadjaa, M; Gorbounova, V; Grossi, F; Kowalski, DM; Reck, M; Rey, A; von Pawel, J | 1 |
Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M | 1 |
Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E | 1 |
Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y | 1 |
Liu, LH; Liu, YH; Xu, L; Yang, H | 1 |
Brachova, P; Button, AM; Carlson, MJ; Dai, D; Devor, EJ; Goodheart, MJ; Leslie, KK; Mott, SL; Mueting, SR; Thiel, KW | 1 |
Aloisi, A; Angioli, R; Capriglione, S; De Cicco Nardone, C; Luvero, D; Miranda, A; Montera, R; Plotti, F; Scaletta, G; Terranova, C | 1 |
Altinok, T; Aribas, O; Artac, M; Boruban, MC; Bozcuk, H; Dede, I; Demirkazik, A; Geredeli, C; Guler, T; Inal, A; Karaagac, M; Koral, L; Yildirim, S; Zamani, AG | 1 |
Braicu, I; Olschewski, J; Sehouli, J; Vasconcelos, I | 1 |
Jansaka, N; Suprasert, P | 1 |
Hiura, K; Iwaki-Egawa, S; Komori, H; Shiraishi, A; Suzuki, C; Takamura, K; Watanabe, Y; Yamamoto, M | 1 |
Arcangeli, V; Brandes, AA; Cecere, SC; Cinieri, S; Daniele, G; Di Maio, M; Di Napoli, M; Gallo, C; Lorusso, D; Maltese, G; Mosconi, AM; Orditura, M; Panici, PB; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Ricci, C; Salutari, V; Sambataro, D; Scambia, G; Tamberi, S | 1 |
Caponigro, F; Clement, PM; Cohen, EE; Cong, XJ; Cupissol, D; de Castro, G; de Souza Viana, L; Del Campo, JM; Ehrnrooth, E; Fayette, J; Gauler, T; Grau, JJ; Guigay, J; Haddad, RI; Keilholz, U; Licitra, LF; Machiels, JP; Tahara, M; Vermorken, JB | 2 |
Bail, JP; Brigand, C; Collet, D; Gronnier, C; Lebreton, G; Luc, G; Mabrut, JY; Mariette, C; Meunier, B | 1 |
Achatz, MI; Baiocchi, G; da Costa, AA; Guimarães, AP; Mantoan, H; Saito, A; Sanches, S; Valadares, CV | 1 |
Blumenschein, GR; Canales, JR; Ginsberg, LE; Heymach, JV; Kies, MS; Lee, JJ; Lin, H; Lu, C; Massarelli, E; Papadimitrakopoulou, V; Tran, HT; Williams, MD | 1 |
Abiko, K; Baba, T; Chikuma, S; Hamanishi, J; Honjo, T; Hosoe, Y; Ikeda, T; Kanai, M; Kawaguchi, A; Konishi, I; Mandai, M; Matsumoto, S; Matsumura, N; Minami, M; Mori, Y; Morita, S; Murayama, T; Shimizu, A; Ueda, A; Yamaguchi, K; Yokode, M | 1 |
Cianci, S; Costantini, B; De Iaco, P; Fagotti, A; Perrone, M; Petrillo, M; Ronsini, C; Scambia, G | 1 |
Adkins, D; Aguilar, JL; Bryant, K; Chang, SC; Chen, E; Chin, S; Ernst, S; He, S; Lee, HJ; Misiukiewicz, K; Obasaju, CK; Soulières, D | 1 |
Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W | 1 |
Hanvoravongchai, P; Havanond, P; Khempech, N; Luealon, P; Vasuratna, A | 1 |
Chang, Y; Chang, YH; Chuang, CM; Lee, WH; Lu, CH; Peng, CW | 1 |
Almorsy, W; Elshebeiny, M | 1 |
Ayhan, A; Burges, A; Creemers, GJ; Davies, L; Gebski, V; Hilpert, F; Huizing, M; Kristensen, G; Lee, CK; Lindemann, K; Lykka, M; Mirza, MR; Pujade-Lauraine, E; Raspagliesi, F; Romero, I; Rubio, MJ | 1 |
Li, L; Wang, Q; Wu, WJ; Zhang, W | 1 |
Däster, S; Delko, T; Droeser, RA; Güth, U; Kraljević, M; Mechera, R; Singer, G; Stadlmann, S; Terracciano, L; Weixler, B | 1 |
Berns, EM; Braicu, EI; Brown, R; Castillo-Tong, DC; Cunnea, P; Darb-Esfahani, S; Flanagan, JM; Flower, K; Gabra, H; Gallon, J; Hergovich, A; Koo, C; Kreuzinger, C; Loomis, E; Masrour, N; Paul, J; Sehouli, J; Siddiqui, N; Vanderstichele, A; Vergote, I; Wilhelm-Benartzi, C; Wilson, A; Wisman, GBA | 1 |
Brown, J; Burzawa, JK; Byers, LA; Coleman, RL; Frumovitz, M; Munsell, MF; Ramalingam, P | 1 |
Allen, AR; Bell-McGuinn, KM; Brenton, JD; Coleman, RL; Cragun, JM; Floquet, A; Giordano, H; Goble, S; Harding, TC; Harrell, MI; Isaacson, J; Kaufmann, SH; Konecny, GE; Kristeleit, RS; Leary, A; Lin, KK; Ma, L; Maloney, L; Mann, E; McNeish, IA; O'Malley, DM; Oaknin, A; Oza, AM; Raponi, M; Ray-Coquard, I; Rolfe, L; Scott, CL; Sun, J; Swisher, EM; Tinker, AV; Yelensky, R | 1 |
Afghahi, A; Carlson, RW; Chang, PJ; Ford, JM; Hartman, AR; Jensen, KC; Kurian, AW; Schackmann, E; Telli, ML; Timms, KM; Vinayak, S | 1 |
Arranz, JÁ; Azrilevich, A; Baron, A; Bedke, J; Bracarda, S; Galsky, MD; Grimm, MO; Krishnan, S; Lambert, A; Necchi, A; Ohyama, C; Pal, S; Plimack, ER; Qu, X; Retz, M; Saci, A; Sharma, P; Siefker-Radtke, A; Vaena, D | 1 |
Aimone, P; Alyasova, A; Barone, C; Chakravartty, A; Chol, M; Dechaphunkul, A; Erfán, J; Faivre, S; Hirawat, S; Karpenko, A; Kasper, S; Kim, SB; Kiss, LA; Li, SH; Licitra, L; Lin, JC; Mesía, R; Nagarkar, R; Ochsenreither, S; Remenár, É; Soulières, D; Tamás, L; Turri, S | 1 |
Ansari, J; Buckley, L; Fernando, I; Tanguay, JS | 1 |
Güth, U; Huang, DJ; Schötzau, A; Wight, E | 1 |
Markman, M | 2 |
Bhore, R; Heffernan, TP; Lea, JS; Schorge, JO; Wingo, SN | 1 |
Del Conte, G; Sessa, C | 1 |
Benasso, M; Erfán, J; Hitt, R; Kawecki, A; Licitra, L; Mesia, R; Remenár, É; Rivera, F; Rottey, S; Senger, S; Störkel, S; Stroh, C; Vermorken, JB; Zabolotnyy, D | 1 |
Groenewegen, G; Kronemeijer, RH; Los, M; van der Mijn, KJ; Voest, EE; Witteveen, PO | 1 |
Eguchi, K; Ichinose, Y; Kishi, K; Minato, K; Nishikawa, M; Nogami, N; Okamoto, H; Seki, N; Seto, T; Shinkai, T; Takiguchi, Y; Watanabe, K | 1 |
Boren, TP; Miller, DS | 1 |
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
Kajiura, Y; Yagata, H; Yamauchi, H | 1 |
Bennouna, J; de Castro, J; Dingemans, AM; Gridelli, C; Griesinger, F; Grossi, F; Langer, C; Rossi, A; Thatcher, N; Wong, EK | 1 |
Bischofs, E; Eichbaum, M; Eickhoff, R; Fehm, T; Fersis, N; Fricke, HC; Gebauer, G; Lenz, F; Mayer, C; Schmidt, M; Schneeweiss, A; Sohn, C; Solomayer, E; Wallwiener, M | 1 |
Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K | 1 |
Argiris, A; Ballas, MS; Belani, CP; Davies, A; Edelman, M; Gandara, DR; Gitlitz, BJ; Groshen, S; Hoffman, P; Koczywas, M; Liu, SV; Ramalingam, S; Tsao-Wei, DD; Vokes, EE | 1 |
Boran, N; Celik, B; Hizli, D; Isikdogan, Z; Karabuk, E; Kose, MF; Tulunay, G; Turan, T; Yilmaz, S | 1 |
Altınbaş, SK; Boran, N; Celik, B; Hızlı, D; Köse, MF; Turan, T; Yılmaz, S | 1 |
Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A | 1 |
Blank, S; Boyd, L; Czok, S; Eberhardt, S; Lee, SJ; Muggia, F; Muller, CY; Pothuri, B; Rutledge, T; Verschraegen, CF | 1 |
du Bois, A; Harter, P; Heitz, F | 1 |
Costantini, B; Fagotti, A; Fanfani, F; Margariti, PA; Petrillo, M; Piovano, E; Scambia, G; Turco, LC; Vizzielli, G | 1 |
Buyukberber, S; Elkiran, ET; Gumusay, O; Inal, A; Isikdogan, A; Kaplan, MA; Kucukoner, M; Ozdemir, N; Ulas, A; Unal, O; Urakci, Z; Yaman, S | 1 |
Blair, E; Cohen, EE; Golden, DW; Haraf, DJ; Nwizu, T; Rudra, S; Stenson, KM; Vokes, EE; Witt, ME | 1 |
Baumann, K; Belau, A; Bentley, J; Berton-Rigaud, D; Brown, C; Canzler, U; Friedlander, M; Gebski, V; Kristensen, G; Kurzeder, C; Ledermann, JA; Lee, CK; Lord, SJ; Nankivell, M; Parma, G; Pfisterer, J; Pisano, C; Plante, M; Pujade-Lauraine, E; Schauer, C; Simes, RJ; Skeie-Jensen, T; Swart, AM; Vergote, I | 1 |
Cohen, J; Halm, EA; Mandeli, J; Mhango, G; Sigel, K; Strauss, G; Wisnivesky, J | 1 |
Chen, Z; Liang, Z; Wang, L; Wang, S; Yang, L; Zeng, S | 1 |
Bang, YJ; Choi, IS; Han, SW; Im, SA; Kang, EJ; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
Arias-Pulido, H; Bauman, JE; Bishop, J; Chung, CH; Fekrazad, MH; Fertig, E; Howard, J; Jones, DV; Lee, SJ; Olson, GT; Ozawa, H; Spafford, MJ; Wang, H | 1 |
Agarwal, R; Blagden, S; Diamantis, N; Gabra, H; Shaboodien, R | 1 |
Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
Dorey, F; Eckardt, J; Eilber, FC; Eilber, FR; Nelson, SD; Rosen, G; Selch, M | 1 |
Goff, BA; Greer, BE; Jacobs, A; Storer, B; Thompson, T | 1 |
Berman, ML; Cappuccini, F; Chan, JK; DiSaia, PJ; Loizzi, V; Osann, K | 1 |
Belinson, J; Kulp, B; Markman, J; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
Engelholm, SA; Gronlund, B; Horvath, G; Mäenpää, J; Ridderheim, M | 1 |
Bast, RC; Clark, EA; Cliby, WA; Damokosh, AI; Gershenson, D; Hartmann, LC; Hoersch, S; Iartchouk, N; Kalli, KR; Kaufmann, SH; Lillie, J; Linette, GP; Lu, KH; Ross, JS; Shridhar, V; Smith, DI; Stec, J | 1 |
Baron, M; Blanchot, J; Bonnier, P; Castaigne, D; Classe, JM; Duvillard, P; Leblanc, E; Lhommé, C; Morice, P; Querleu, D; Rey, A | 1 |
Case, AS; Estes, JM; Partridge, EE; Rocconi, RP; Straughn, JM | 1 |
Angioli, R; Basile, S; Bellati, F; Benedetti Panici, P; De Vivo, A; Manci, N; Muzii, L; Perniola, G | 1 |
Boku, N; Ebihara, M; Iida, Y; Onitsuka, T; Onozawa, Y; Zenda, S | 1 |
Ervin, TJ; Fabian, RL; Miller, D; Norris, CM; Posner, MR; Rose, C; Weichselbaum, RR | 1 |
Gall, HE; Klein, I; Pinedo, HM; van der Vijgh, WJ; Vermorken, JB | 1 |
Hoskins, WJ; Jones, WB; Lewis, JL; Rubin, SC; Vaccarello, L; Vlamis, V; Wong, G | 1 |
Cromeens, DM; Curley, SA; Davidson, BS; Izzo, F; Siddik, ZH; Stephens, LC | 1 |
Gore, ME; Taylor, AE | 1 |
Fluellen, L; Fusco, N; Rodriguez, M; Rose, PG | 1 |
Alzieu, C; Cowen, D; Hannoun-Levi, JM; Resbeut, M | 1 |
Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
Atkinson, N; Castellanos, AM; Choksi, AJ; Dimery, IW; Felder, TB; Hong, WK; McCarthy, K; Newman, RA; Paredes, J; Robbins, KT | 1 |
Chambers, JT; Chambers, SK; Kohorn, EI; Lawrence, R; Schwartz, PE | 1 |
18 review(s) available for platinum and Local Neoplasm Recurrence
Article | Year |
---|---|
Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Europe; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; United States | 2021 |
Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Humans; Induction Chemotherapy; Leukopenia; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Platinum | 2022 |
Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Network Meta-Analysis; Platinum; Vinorelbine | 2022 |
Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Topics: Aged; Head and Neck Neoplasms; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Sunitinib; Thymoma; Thymus Neoplasms | 2023 |
Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.
Topics: Biomarkers; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Quality of Life; Tumor Microenvironment | 2023 |
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2023 |
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Network Meta-Analysis; Ovarian Neoplasms; Platinum; Polyethylene Glycols | 2023 |
Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
Topics: B7-H1 Antigen; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Disease Progression; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Platinum; Urinary Bladder Neoplasms | 2023 |
Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis.
Topics: B7-H1 Antigen; Humans; Immune Checkpoint Inhibitors; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Platinum | 2023 |
Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer.
Topics: Disease Management; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis | 2019 |
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
Topics: Antineoplastic Agents; Disease Management; Drug Design; Drug Discovery; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Salvage Therapy | 2019 |
Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Cost-Benefit Analysis; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Network Meta-Analysis; Nivolumab; Platinum; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Registries; Squamous Cell Carcinoma of Head and Neck; United States | 2021 |
Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Taxoids | 2018 |
A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants.
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Drug Implants; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Treatment Outcome | 2015 |
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma | 2016 |
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Platinum; Receptors, Estrogen; Taxoids | 2011 |
Natural history and treatment of malignant thymoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Radiotherapy, Adjuvant; Thymectomy; Thymoma; Thymus Neoplasms | 1998 |
64 trial(s) available for platinum and Local Neoplasm Recurrence
Article | Year |
---|---|
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phenylurea Compounds; Platinum; Pyridines; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Treatment Outcome | 2022 |
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea | 2022 |
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Topics: BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Germ Cells; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum | 2022 |
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Topics: Aniline Compounds; Carcinoma, Ovarian Epithelial; Female; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Thrombocytopenia | 2022 |
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial.
Topics: Adenocarcinoma, Clear Cell; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Quality of Life; Tumor Microenvironment | 2022 |
A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Recurrence, Local; Platinum; Taxoids | 2022 |
Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Humans; Immune Checkpoint Inhibitors; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Uterine Cervical Neoplasms; Young Adult | 2022 |
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Programmed Cell Death 1 Receptor; Ramucirumab | 2022 |
Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Purines | 2022 |
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Platinum | 2022 |
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Fluorouracil; Head and Neck Neoplasms; Humans; Japan; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Topics: BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 month
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Trabectedin | 2023 |
Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Leukopenia; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Topotecan | 2023 |
Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Treatment Outcome | 2023 |
Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
Topics: Disease Progression; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2023 |
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.
Topics: Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Platinum; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Survival Analysis | 2023 |
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Quality of Life | 2023 |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2019 |
An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pilot Projects; Platinum; Republic of Korea | 2019 |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Platinum; Taiwan | 2020 |
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Drug-Related Side Effects and Adverse Reactions; Female; Gene Amplification; Humans; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Platinum; Progression-Free Survival; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines; Pyrimidinones; Rapamycin-Insensitive Companion of mTOR Protein; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53 | 2020 |
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Squamous Cell Carcinoma of Head and Neck | 2020 |
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Docetaxel; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum | 2021 |
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; DNA Methylation; DNA-Binding Proteins; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Promoter Regions, Genetic | 2021 |
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CA-125 Antigen; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Progression-Free Survival; Survival Rate; Treatment Outcome | 2021 |
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind
Topics: Administration, Intravenous; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Pharmaceutical Preparations; Platinum; Quality of Life; Randomized Controlled Trials as Topic; Selenium | 2021 |
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Platinum; Quinolines | 2021 |
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan | 2018 |
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Capsules; Cystadenocarcinoma, Serous; Disease-Free Survival; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Treatment Outcome; Young Adult | 2018 |
Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Ovarian Neoplasms; Platinum; Prognosis; Prospective Studies; Survival Rate | 2019 |
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; MutL Protein Homolog 1; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Platinum | 2014 |
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Serine; Taxoids; Treatment Outcome | 2014 |
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck | 2014 |
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Lenalidomide; Membrane Proteins; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Thalidomide | 2014 |
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Italy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrimidines; Sulfonamides; Treatment Outcome | 2015 |
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Survival Rate | 2015 |
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Programmed Cell Death 1 Receptor; Salvage Therapy; Survival Rate | 2015 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemistry, Pharmaceutical; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2016 |
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Response Evaluation Criteria in Solid Tumors | 2016 |
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Topics: Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Germ-Line Mutation; Humans; Indoles; International Agencies; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2017 |
Tumor
Topics: Aged; BRCA1 Protein; BRCA2 Protein; Carboplatin; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Platinum; Triple Negative Breast Neoplasms | 2017 |
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Transitional Cell; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Platinum; Prognosis; Survival Rate; Urologic Neoplasms | 2017 |
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Double-Blind Method; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; International Agencies; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Survival Rate | 2017 |
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Fluorouracil; Gene Dosage; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Pyrrolidines; Survival Analysis; Treatment Outcome; Vomiting | 2010 |
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Platinum; Salvage Therapy; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2011 |
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2011 |
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Pyrimidines; Sulfonamides | 2011 |
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids | 2013 |
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Ethers, Cyclic; Female; Follow-Up Studies; Furans; Humans; Ketones; Lung Neoplasms; Macrolides; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2012 |
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2012 |
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Taxoids; Treatment Outcome | 2012 |
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Platinum; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6 Kinases; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2013 |
Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome; Washington | 2003 |
Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Administration Schedule; Etoposide; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Taxoids; Topotecan | 2005 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Ditiocarb; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Kidney; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Random Allocation | 1988 |
157 other study(ies) available for platinum and Local Neoplasm Recurrence
Article | Year |
---|---|
Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2021 |
Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Platinum; Retrospective Studies | 2022 |
New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Recurrence, Local; Platinum; Prognosis; Retrospective Studies; Stomach Neoplasms | 2021 |
Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum-based chemotherapy.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Retrospective Studies | 2022 |
Survival in recurrent ovarian cancer patients before and after the bevacizumab era: an observational single-centre study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2022 |
Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Mice; Nanoparticles; Neoplasm Recurrence, Local; Platinum; Prodrugs; Tumor Microenvironment | 2022 |
Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy.
Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum | 2022 |
Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Mangifera; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Retrospective Studies | 2022 |
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Topics: Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Topics: Animals; Cisplatin; Female; Humans; Mitochondria; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Ovarian Neoplasms; Oxidative Phosphorylation; Platinum; Sirtuin 1 | 2022 |
Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carbohydrates; Carcinoma, Ovarian Epithelial; Female; Humans; MicroRNAs; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2022 |
Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Retrospective Studies | 2022 |
Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Data Analysis; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Platinum; Retrospective Studies | 2023 |
Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Quinolines; Small Cell Lung Carcinoma | 2022 |
Assessment of Tumor Heterogeneity in High-Grade Serous Ovarian Cancer: Mass Cytometry to Understand the Complex Tumor Biology.
Topics: Biology; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2022 |
Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Recurrence, Local; Platinum; Radiotherapy, Conformal; Retrospective Studies | 2022 |
Combined taxane, platinum, and cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2022 |
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum; Prognosis; Retrospective Studies | 2022 |
Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
Topics: Carcinoma, Ovarian Epithelial; Cell Line; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Single-Cell Analysis; Transcriptome | 2022 |
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers.
Topics: Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Serine | 2022 |
Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Recurrence | 2023 |
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies | 2022 |
Mutational landscape of homologous recombination-related genes in small-cell lung cancer.
Topics: B7-H1 Antigen; Biomarkers, Tumor; Homologous Recombination; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2022 |
Role of salvage radiotherapy for recurrent ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies; Salvage Therapy | 2023 |
Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2022 |
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Progression-Free Survival; Retrospective Studies | 2022 |
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; ErbB Receptors; Head and Neck Neoplasms; Humans; Inflammation; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report.
Topics: Antineoplastic Agents, Immunological; Apoptosis; B7-H1 Antigen; Carcinoma, Ovarian Epithelial; Female; HLA-B44 Antigen; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Programmed Cell Death 1 Receptor | 2022 |
Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer.
Topics: Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Comparison of real-world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials.
Topics: Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Recurrence, Local; Platinum; Randomized Controlled Trials as Topic; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome.
Topics: Carcinoma, Ovarian Epithelial; DNA Damage; Female; Humans; Machine Learning; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2023 |
Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study.
Topics: Alberta; Cohort Studies; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Platinum; Retrospective Studies | 2023 |
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; NF-E2-Related Factor 2; Platinum; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Taxoids | 2023 |
A platinum(II) complex HY1-Pt overcomes cisplatin-induced resistance and attenuates metastasis of epithelial ovarian cancer by cancer cell stemness inhibition.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Casein Kinase II; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2023 |
Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Epigenomics; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2023 |
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cystadenocarcinoma, Serous; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies | 2023 |
The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Analgesics, Opioid; Antibodies, Monoclonal; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; Female; Head and Neck Neoplasms; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2023 |
ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Reactive Oxygen Species; src-Family Kinases | 2023 |
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Topics: Carcinoma, Squamous Cell; Double-Blind Method; Head and Neck Neoplasms; Humans; Immunotherapy; Ipilimumab; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Topics: Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
Exceptional Response of Pancreatic Acinar Cell Carcinoma and Bile Duct Cancer to Platinum-Based Chemotherapy in a Family With a Germline BRCA2 Variant.
Topics: Adult; Bile Duct Neoplasms; BRCA1 Protein; BRCA2 Protein; Carcinoma, Acinar Cell; Genetic Predisposition to Disease; Germ Cells; Germ-Line Mutation; Humans; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Platinum | 2022 |
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Topics: Animals; Etoposide; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-myc; Small Cell Lung Carcinoma | 2023 |
Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis | 2023 |
Decision-making for Subsequent Therapy for Patients With Recurrent or Advanced Endometrial Cancer Based on the Platinum-free Interval.
Topics: Antineoplastic Combined Chemotherapy Protocols; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Platinum; Retrospective Studies | 2023 |
Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Recurrence, Local; Platinum; Protein Kinase Inhibitors; Retrospective Studies | 2023 |
Platinum-combination chemotherapy with or without immune-checkpoint inhibitor in patients with postoperative recurrent non-small cell lung cancer previously treated with adjuvant platinum-doublet chemotherapy: A multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Retrospective Studies | 2023 |
Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies | 2023 |
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Topics: Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Recurrence; Retrospective Studies; Ribose | 2023 |
Chemotherapy-free, but not quite free chemotherapy.
Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum | 2019 |
Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.
Topics: Aged; Biomarkers, Tumor; Calbindin 2; Case-Control Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Longitudinal Studies; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Survival Rate | 2020 |
Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study.
Topics: Cisplatin; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Neoplasm Recurrence, Local; Platinum; Prospective Studies | 2019 |
Chemotherapy-free strategy for platinum-sensitive recurrent ovarian cancer.
Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum | 2019 |
Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Pyrimidines; Retrospective Studies; Sulfonamides | 2020 |
Platinum-sensitive ovarian cancer: liminal advances.
Topics: Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2020 |
Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2020 |
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Treatment Outcome | 2020 |
[Efficacy of Olaparib Treatment for Platinum-Sensitive Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancers].
Topics: Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum | 2020 |
Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2020 |
Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
Topics: Antibodies, Monoclonal, Humanized; China; Cost-Benefit Analysis; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Platinum; Quality-Adjusted Life Years; Squamous Cell Carcinoma of Head and Neck | 2020 |
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Rad51 Recombinase | 2021 |
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Topics: Administration, Oral; Aged; Area Under Curve; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2021 |
A Single Arm Prospective Pilot Study Examining the Efficacy and Safety of Bevacizumab Single Maintenance Therapy Following Platinum-Based Chemotherapy in Patients with Advanced or Recurrent Cervical Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Platinum; Prospective Studies; Uterine Cervical Neoplasms | 2021 |
Taxane-based versus platinum-based chemotherapy in early recurrent gastric cancer after radical surgery with S-1 adjuvant chemotherapy: A multi-institutional retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Humans; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Stomach Neoplasms; Taxoids | 2022 |
The Plasticity of Circulating Tumor Cells in Ovarian Cancer During Platinum-containing Chemotherapy.
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Epithelial Cell Adhesion Molecule; Humans; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Ovarian Neoplasms; Platinum | 2021 |
Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; BRCA1 Protein; BRCA2 Protein; Female; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Young Adult | 2021 |
Epithelial Ovarian Cancer and Cancer Stem Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Platinum | 2021 |
Comparisons of survival outcomes between bevacizumab and olaparib in
Topics: Bevacizumab; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Republic of Korea | 2021 |
Epidemiology and Outcomes with Platinum-Based Chemotherapy in Recurrent or Metastatic Carcinoma Cervix in a Developing Country: Experience from a Tertiary Oncology Centre in Southern India.
Topics: Developing Countries; Female; Humans; India; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Tertiary Care Centers; Uterine Cervical Neoplasms | 2017 |
Primary mediastinal yolk sac tumor treated with platinum-based chemotherapy and extended resection: Report of seven cases.
Topics: Adolescent; Adult; Endodermal Sinus Tumor; Humans; Male; Mediastinal Neoplasms; Mediastinum; Neoplasm Recurrence, Local; Platinum; Postoperative Complications; Prognosis; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2018 |
Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.
Topics: Aged; Animals; Antigens, Neoplasm; Caenorhabditis elegans; CD8-Positive T-Lymphocytes; Chickens; Female; Gene Expression Regulation, Neoplastic; Genome; High-Throughput Nucleotide Sequencing; Humans; Macrophages; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Ovarian Neoplasms; Platinum | 2018 |
Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Hysterectomy; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Platinum; Postoperative Care; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Uterine Cervical Neoplasms; Young Adult | 2018 |
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Topics: Aged; BRCA1 Protein; BRCA2 Protein; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Risk Assessment | 2018 |
Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine.
Topics: Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2018 |
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Analysis and treatment of 45 platinum-allergic gynecologic malignant tumors.
Topics: Adult; Aged; China; Desensitization, Immunologic; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Risk Factors; Skin Tests | 2018 |
Treatment of platinum refractory or resistant ovarian cancer.
Topics: Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sorafenib; Topotecan | 2018 |
Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer Patients.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cohort Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Survival Analysis; United States | 2019 |
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Disease Progression; DNA Methylation; Female; High-Throughput Nucleotide Sequencing; Homologous Recombination; Humans; Loss of Heterozygosity; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sequence Analysis, DNA; Young Adult | 2018 |
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Topotecan | 2019 |
Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies; Trabectedin | 2019 |
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Practice Patterns, Physicians'; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2019 |
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Topics: Antineoplastic Agents; Budgets; Female; Health Expenditures; Humans; Indazoles; Models, Econometric; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Survival Analysis; United States | 2019 |
ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cystadenocarcinoma, Serous; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Platinum; Prognosis; Tumor Suppressor Proteins | 2019 |
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies | 2019 |
Stromal cell ratio based on automated image analysis as a predictor for platinum-resistant recurrent ovarian cancer.
Topics: Aged; Biomarkers, Tumor; CA-125 Antigen; Chi-Square Distribution; Drug Resistance, Neoplasm; Drug Therapy; Female; Humans; Image Processing, Computer-Assisted; Logistic Models; Membrane Proteins; Neoplasm Recurrence, Local; Odds Ratio; Ovarian Neoplasms; Platinum; Stromal Cells; Tumor Microenvironment | 2019 |
Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Middle Aged; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Rate; United States; Young Adult | 2019 |
Chemotherapy-free treatments: are we ready for prime time?
Topics: Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Progression-Free Survival; Quinazolines; Time | 2019 |
Radiotherapy for isolated recurrent epithelial ovarian cancer: A single institutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Ovarian Neoplasms; Platinum; Radiotherapy; Retrospective Studies; Survival Analysis | 2019 |
[Ⅲ.Surgery for Platinum Sensitive Recurrent Epithelial Ovarian Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum | 2019 |
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Retrospective Studies; Survival Rate; Trabectedin | 2019 |
Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Platinum; Retrospective Studies | 2020 |
Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Middle Aged; Models, Statistical; Neoplasm Recurrence, Local; Nomograms; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Prospective Studies; Severity of Illness Index; Survival Rate; Taxoids | 2019 |
Ovarian Cancer Treatment Stratification Using
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Platinum | 2019 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Survival Rate | 2013 |
Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endostatins; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cohort Studies; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Risk Assessment; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2015 |
[Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Genotype; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide; Prognosis; Young Adult | 2013 |
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Palliative Care; Peritoneal Neoplasms; Platinum; Prognosis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires | 2014 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Efficacy of permanent iodine-125 seed implants and gemcitabine chemotherapy in patients with platinum- resistant recurrent ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Brachytherapy; Chemoradiotherapy; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Tomography, X-Ray Computed | 2014 |
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Topics: Adult; Aged; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Taxoids; Tumor Suppressor Protein p53 | 2015 |
Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2015 |
Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Prognosis; Tumor Suppressor Protein p53; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2015 |
Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tertiary Care Centers | 2014 |
MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Blood Cell Count; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Neutrophils; Paclitaxel; Platinum; Vascular Endothelial Growth Factor A | 2015 |
Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; France; Humans; Incidence; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Risk Factors; Survival Rate | 2015 |
Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Topotecan | 2016 |
Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Databases, Factual; Disease-Free Survival; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Propensity Score | 2016 |
Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum | 2016 |
[Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; China; Computational Biology; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Proteomics; ROC Curve; Treatment Outcome | 2016 |
MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity.
Topics: Adult; Aged; Biomarkers, Tumor; Female; Humans; Interleukin-17; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peroxidase; Platinum; Regression Analysis; Survival Analysis; Tissue Array Analysis; Treatment Outcome | 2016 |
Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.
Topics: Aged; Cell Line, Tumor; DNA Adducts; DNA Damage; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Promoter Regions, Genetic | 2017 |
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Young Adult | 2017 |
Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment.
Topics: CA-125 Antigen; Carcinoma, Papillary; Cohort Studies; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Is the current concept of recurrent ovarian carcinoma as a chronic disease also applicable in platinum resistant patients?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies | 2010 |
Chemotherapy: Topotecan or treosulfan--that is the question.
Topics: Antineoplastic Agents; Busulfan; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance; Drug Therapy; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Survival Analysis; Time Factors; Topotecan | 2009 |
Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Platinum; Reoperation; Retrospective Studies | 2010 |
Targeted therapies: tailored treatment for ovarian cancer: are we there yet?
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Taxoids; Treatment Outcome | 2010 |
Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Taxoids | 2010 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Role of chemotherapy in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Taxoids | 2011 |
Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome | 2012 |
Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Surgery for relapsed ovarian cancer: when should it be offered?
Topics: Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Platinum; Prognosis; Randomized Controlled Trials as Topic | 2012 |
Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up.
Topics: Adult; Aged; Case-Control Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Survival Analysis | 2012 |
Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Etoposide; Female; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2012 |
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Hydroxyurea; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2013 |
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nomograms; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Sensitivity and Specificity; Treatment Outcome | 2013 |
Outcomes after adjuvant platinum-based chemotherapy in elderly NSCLC patients with T4 disease.
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; SEER Program; Survival Rate | 2013 |
A novel CD105 determination system based on an ultrasensitive bioelectrochemical strategy with Pt nanoparticles.
Topics: Antigens, CD; Biosensing Techniques; Early Detection of Cancer; Electrochemical Techniques; Endoglin; Humans; Immunoassay; Metal Nanoparticles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Receptors, Cell Surface | 2012 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Patient Selection; Platinum; Prognosis; Survival Rate | 2013 |
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Doxorubicin; Extremities; Female; Humans; Ifosfamide; Limb Salvage; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Platinum; Prognosis; Radiotherapy; Risk Factors; Sarcoma; Survival Analysis; Treatment Outcome | 2003 |
Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Survival Analysis; Treatment Outcome | 2003 |
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Research Design; Retrospective Studies; Time Factors | 2004 |
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate | 2005 |
Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique).
Topics: Adolescent; Adult; Antineoplastic Agents; Female; Fertility; Follow-Up Studies; Humans; Hysterectomy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Platinum; Pregnancy; Retrospective Studies; Survival Rate | 2005 |
Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2006 |
Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Observation; Ovarian Neoplasms; Platinum; Prognosis; Prospective Studies | 2007 |
Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Tolerance; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Taxoids; Treatment Outcome | 2007 |
The role of chemotherapy for advanced carcinoma of the supraglottic and glottic larynx.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Glottis; Humans; Laryngeal Neoplasms; Methotrexate; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Platinum | 1984 |
Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Infusions, Parenteral; Kinetics; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Tongue Neoplasms | 1982 |
Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response.
Topics: Abdominal Neoplasms; Adult; Aged; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Laparotomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Pelvic Neoplasms; Platinum; Reoperation; Retrospective Studies; Survival Analysis | 1995 |
Collagen matrix cisplatin prevents local tumor growth after margin-positive resection.
Topics: Animals; Cisplatin; Collagen; Combined Modality Therapy; Drug Delivery Systems; Male; Neoplasm Recurrence, Local; Neoplasms, Experimental; Platinum; Rabbits | 1995 |
Chlorambucil for platinum-refractory ovarian cancer.
Topics: Adult; Aged; Carcinoma; Chlorambucil; Combined Modality Therapy; Drug Resistance; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Remission Induction; Retrospective Studies; Survival Rate | 1994 |
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Treatment Outcome | 1998 |
Evaluation of the role of second-look surgery in ovarian cancer.
Topics: Adolescent; Adult; Aged; Carcinoma; Combined Modality Therapy; Evaluation Studies as Topic; False Negative Reactions; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Regression Analysis; Reoperation; Retrospective Studies; Surgical Procedures, Operative; Time Factors | 1988 |